3-deazaneplanocin has been researched along with deoxycytidine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avan, A; Crea, F; Danesi, R; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Marquez, VE; Paolicchi, E; Peters, GJ | 1 |
| Bhutia, YD; Cho, JH; Chu, CK; Davis, F; Dhar, S; Govindarajan, R; Hung, SW; Marrache, S; Mody, H; Zastre, J | 1 |
| Baba, H; Beppu, T; Hashimoto, D; Hayashi, H; Kuroki, H; Mima, K; Nakagawa, S; Okabe, H; Sakamoto, K; Sakamoto, Y; Tokunaga, R; Yokoyama, N | 1 |
| Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK | 1 |
4 other study(ies) available for 3-deazaneplanocin and deoxycytidine
| Article | Year |
|---|---|
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Topics: AC133 Antigen; Adenosine; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Delayed-Action Preparations; Deoxycytidine; DNA Methylation; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Nanoparticles; Nucleosides; Pancreatic Neoplasms; Xenopus | 2013 |
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Polycomb Repressive Complex 2; RNA Interference; RNA, Small Interfering | 2014 |
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |